FindTrial
Sign In

Real-world Study of Toripalimab in the Application of Advanced Hepatocellular Carcinoma

Application Demonstration Project of Toripalimab in Advanced Hepatocellular Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116531
Enrollment
Unknown
Registered
2026-01-12
Start date
2026-02-09
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced unresectable hepatocellular carcinoma

Interventions

Observation group:None

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Voluntarily participate in the study and sign the informed consent form; 2.Be diagnosed with advanced hepatocellular carcinoma by imaging or pathological examination; 3.Be receiving or scheduled to receive toripalimab treatment; 4.Have traceable medical records during the treatment period.

Exclusion criteria

Exclusion criteria: 1.Females who are pregnant or lactating; 2.Subjects with known allegery to recombinant humanized anti-PD-1 monoclonal antibody drugs and their components; 3.Other circumstances that are deemed inappropriate for inclusion in the study by the investigators.

Design outcomes

Primary

MeasureTime frame
Real-world progression-free survival, rwPFS;—

Secondary

MeasureTime frame
Safety;Real-world overall survival, rwOS;Real-world objective response rate, rwORR;Real-world disease control rates, rwDCR;—

Countries

China

Contacts

Public ContactJian Zhou

Zhongshan Hospital, Fudan University

zhou.jian@zs-hospital.sh.cn+86 21 64041990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026